Read by QxMD icon Read

Virus myeloma

Jacques Cosnes
BACKGROUND: Treatment of inflammatory bowel disease (IBD) in patients with prior malignancy is challenging because therapeutic immunosuppression required for controlling IBD activity may increase the risk of cancer recurrence. Key Messages: Contrary to the observations in the post-transplant population, retrospective observational studies of IBD patients with prior malignancy have not demonstrated that immunosuppressive drugs increased significantly the risk of new or recurrent cancer...
2017: Digestive Diseases
Ankur Varma, Laura Biritxinaga, Rima M Saliba, Maximilian Stich, Sarah Francesca Jauch, Aimaz Afrough, Medhavi Honhar, Uday R Popat, Mehnaz A Shafi, Nina Shah, Qaiser Bashir, Yvonne Dinh, Chitra Hosing, Richard E Champlin, Muzaffar H Qazilbash
Hepatitis B core antibody (HBcAb) seropositivity has been associated with a higher rate of hepatitis B virus (HBV) reactivation after chemotherapy, even in patients who are hepatitis B surface antigen (HBsAg) negative. However, little is known about the risk of HBV reactivation after autologous hematopoietic stem cell transplantation (auto-HCT). We evaluated the incidence of HBV reactivation, liver toxicity, and survival in patients with multiple myeloma (MM) who received auto-HCT at our institution. We retrospectively identified 107 MM patients with resolved HBV infection (HBcAb positive, HBsAg negative) and 125 patients with negative HBV serology (control subjects) who were matched for age, timing of auto-HCT from diagnosis, cytogenetics, disease status at transplant, induction therapy, and preparative regimen...
January 4, 2017: Biology of Blood and Marrow Transplantation
Eric Bartee, Mee Y Bartee, Bjarne Bogen, Xue-Zhong Yu
Multiple myeloma is an incurable malignancy of plasma B-cells. Traditional chemotherapeutic regimes often induce initial tumor regression; however, virtually all patients eventually succumb to relapse caused by either reintroduction of disease during autologous transplant or expansion of chemotherapy resistant minimal residual disease. It has been previously demonstrated that an oncolytic virus known as myxoma can completely prevent myeloma relapse caused by reintroduction of malignant cells during autologous transplant...
2016: Molecular Therapy Oncolytics
Kelli Borges Dos Santos, Rafaela Souto E Souza, Angelo Atalla, Abrahão Elias Hallack-Neto
BACKGROUND: The autologous hematopoietic stem cell transplantation procedure involves immunosuppression of the patient. Thus, the patient has an elevated risk for several diseases, such as infections with the varicella-zoster virus. Prevention protocols have been proposed based on the use of acyclovir from the first day of conditioning, and maintaining this drug for 30-100 days after the procedure or for as much as one year. The objective of this work was to evaluate the incidence of herpes zoster after autologous transplantations related to the early suspension of acyclovir...
October 2016: Revista Brasileira de Hematologia e Hemoterapia
Sarah Aref, Katharine Bailey, Adele Fielding
Oncolytic virotherapeutic agents are likely to become serious contenders in cancer treatment. The vaccine strain of measles virus is an agent with an impressive range of oncolytic activity in pre-clinical trials with increasing evidence of safety and efficacy in early clinical trials. This paramyxovirus vaccine has a proven safety record and is amenable to careful genetic modification in the laboratory. Overexpression of the measles virus (MV) receptor CD46 in many tumour cells may direct the virus to preferentially enter transformed cells and there is increasing awareness of the importance of nectin-4 and signaling lymphocytic activation molecule (SLAM) in oncolysis...
October 22, 2016: Viruses
Shun-Quan Wu, Wen-Yan Niu, Ya-Ping Li, Hao-Bo Huang, Rong Zhan
The oncogene B-cell-specific Moloney murine leukemia virus insertion site‑1 (Bmi‑1) is overexpressed in multiple myeloma (MM). Our previous study demonstrated that Bmi‑1 silencing sensitized MM cells to bortezomib. Translational regulation has emerged as a prominent underlying mechanism of Bmi‑1 regulation, particularly via microRNA targeting. The present study determined that Bmi‑1 may be directly targeted by miR‑203 using a luciferase assay. In addition, enforced expression of miR-203 led to significant downregulation of Bmi‑1 protein and mRNA expression levels...
November 2016: Molecular Medicine Reports
M S Dal, A Doğan, A Karakuş, T Dal, M Kaya, O Ayyıldız
A 58-year-old female patient whose serological test results were Hepatitis B surface antigen (HBsAg) negative and Hepatitis B surface antibody (HBsAb) positive, diagnosed with Multiple myeloma. Autologous haematopoietic stem-cell transplantation was subsequently performed after induction chemotherapy. One-year later the patient was diagnosed as Hepatitis B Virus (HBV) reactivation and was started on lamivudine oral therapy. Hepatitis B surface antigen (HBsAg) negative is negative and HBsAb is positive in patients scheduled for chemotherapy, HBV DNA levels should still be investigated...
February 22, 2016: West Indian Medical Journal
Lucía Martínez-Hernández, Diana Vilar-Compte, Patricia Cornejo-Juárez, Patricia Volkow-Fernández
INTRODUCTION: Nosocomial pneumonia (NP) in patients with hematological malignancies (HM) has an attributable mortality over 90%. There are few studies that report the incidence of nosocomial infections in patients with HM. OBJECTIVE: To describe the epidemiology and clinical course of NP in a cohort of patients with hematologic malignancies. MATERIAL AND METHODS: Single-center study of patients with leukemia, lymphoma or multiple myeloma diagnosed with NP, hospitalized between January 2011 and December 2012...
July 2016: Gaceta Médica de México
J Ramachandran, L Santo, K T Siu, C Panaroni, N Raje
Pan proviral integrations of Moloney virus (PIM) inhibition in multiple myeloma (MM) results in reduced cell viability in tested human-derived MM cell lines and reduces tumor burden in xenograft mouse models, making PIMs important therapeutic targets for the disease. PIM kinase inhibitors are currently being tested clinically in MM. We sought to elucidate the role of the various PIMs in MM. Our data demonstrate that Pim2 has a significant role in MM cell cytotoxicity. Our data provide evidence for a novel role for Pim2 in the regulation of the DNA damage response (DDR)...
2016: Blood Cancer Journal
Wen Lei, Shibing Wang, Chunmei Yang, Xianbo Huang, Zhenzhen Chen, Wei He, Jianping Shen, Xinyuan Liu, Wenbin Qian
Despite great progress made in the treatment of multiple myeloma (MM), it is still incurable. Promising phase II clinical results have been reported recently for oncolytic vaccinia virus (OVV) clinic therapeutics. One reason for this has focused on the critical therapeutic importance of the immune response raised by these viruses. However, few studies have performed their applications as an optimal delivery system for therapeutic gene, especially miRNA in MM. In this study, we constructed two novel OVVs (TK deletion) that express anti-tumor genes, miR-34a and Smac, respectively, in MM cell lines and xenograft model...
2016: Scientific Reports
Risturo Arakawa, Nobuaki Mori, Narito Kagawa, Akiko Higuchi, Masashi Tanaka, Yasuko Aoki, Shiko Seki, Ryo Suzuki
Meningococcal infection is among the most devastating diseases. It is rarely seen in Japan. However, several environmental and host factors have been associated with increased risks of Neisseria meningitidis infection. We present a case of invasive N. meningitidis infection that revealed the presence of multiple myeloma. A 55-year-old Japanese man was admitted with fever and altered consciousness. He was sent to the intensive care unit for septic shock and disseminated intravascular coagulation. In addition to standard septic shock and multiple organ failure treatment, polymyxin-B immobilized column direct hemoperfusion was performed...
May 2016: Kansenshōgaku Zasshi. the Journal of the Japanese Association for Infectious Diseases
B Kirushnan, B Subbarao, P Prabhu
ABO incompatible kidney transplant recipients receive higher dose of immunosuppression. Previous data indicate that the incidence of malignancy is not higher in these patients. Compared to the general population, renal transplant recipients are at 4.4-fold higher risk of developing myeloma. We describe a case of posttransplant multiple myeloma in an ABO incompatible renal transplant recipient of a second graft.
July 2016: Indian Journal of Nephrology
Mehar Chand Sharma, Rakesh Kumar Gupta, Seema Kaushal, Vaishali Suri, Chitra Sarkar, Manmohan Singh, S S Kale, Ranjit K Sahoo, Lalit Kumar, Vinod Raina
BACKGROUND & OBJECTIVES: Primary central nervous system lymphomas (PCNSLs) are relatively uncommon, accounting for 2-3 per cent of primary brain tumours. Majority of these are diffuse large B cell lymphomas (DLBCL) occurring both in immunocompromised and immunocompetent patients. We undertook this study to classify PCNSL into germinal centre (GC) and non-germinal centre (NGC) type based on Hans classification and to find the role of Epstein-Barr virus (EBV) in pathogenesis both by conventional immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH)...
May 2016: Indian Journal of Medical Research
Gabriela Alvarado, James E Crowe
Human monoclonal antibodies against RSV have high potential for use as prophylaxis or therapeutic molecules, and they also can be used to define the structure of protective epitopes for rational vaccine design. In the past, however, isolation of human monoclonal antibodies was difficult and inefficient. Here, we describe contemporary methods for activation and proliferation of primary human memory B cells followed by cytofusion to non-secreting myeloma cells by dielectrophoresis to generate human hybridomas secreting RSV-specific monoclonal antibodies...
2016: Methods in Molecular Biology
Vijeev Vasudevan, Yella Ravi Kumar, Prathyusha Chavva, S Naina
Plasmablastic Lymphoma of oral cavity is an aggressive rare form of Non Hodgkin's Lymphoma which is an Acquired Immuno Deficiency Syndrome defining condition. Head and neck region is the second most common area for extranodal NHL's primarily involving gingiva and palate, which often presents as a diagnostic problem. We report a case of PBL in a 19 year old female patient later diagnosed as Human Immunodeficiency Virus (HIV) positive. She presented with expanding painful ulceroproliferative lesion involving left mandible and gingiva of 20 days duration...
May 2016: Indian Journal of Dental Research: Official Publication of Indian Society for Dental Research
Walter Alexander
We report on key Digestive Disease Week sessions that focused on hepatitis C virus and Clostridium difficile infection, colonoscopy preparation, irritable bowel syndrome, and Crohn's disease. We also review major American Society of Clinical Oncology sessions on breast, pancreatic, ovarian, skin, and brain cancers and multiple myeloma.
July 2016: P & T: a Peer-reviewed Journal for Formulary Management
Sarah A Watters, Petra Mlcochova, Frank Maldarelli, Nilu Goonetilleke, Deenan Pillay, Ravindra K Gupta
BACKGROUND: HIV Elite Controllers may reveal insights into virus persistence given they harbour small reservoir sizes, akin to HIV non-controllers treated early with combination antiretroviral therapy. Both groups of patients represent the most promising candidates for interventions aimed at sustained remission or 'cure'. Analytic treatment interruption (ATI) in the latter group leads to stochastic rebound of virus, though it is unclear whether loss of elite control is also associated with similar rebound characteristics...
2016: PloS One
Yutaka Tsukune, Makoto Sasaki, Takeshi Odajima, Atsushi Isoda, Morio Matsumoto, Michiaki Koike, Hideto Tamura, Keiichi Moriya, Shigeki Ito, Maki Asahi, Yoichi Imai, Junji Tanaka, Hiroshi Handa, Hiromi Koiso, Sakae Tanosaki, Jian Hua, Masao Hagihara, Yuriko Yahata, Satoko Suzuki, Sumio Watanabe, Hiroki Sugimori, Norio Komatsu
There are some reports regarding hepatitis B virus (HBV) reactivation in patients with myeloma who are HBV carriers or who have had a resolved HBV infection, and there is no standard prophylaxis strategy for these patients. We performed a retrospective multicenter study to determine the incidence and characteristics of HBV reactivation in patients with multiple myeloma. We identified 641 patients with multiple myeloma who had been treated using novel agents and/or autologous stem cell transplantation with high-dose chemotherapy between January 2006 and June 2014 at nine Japanese hospitals...
September 2016: Annals of Hematology
Richard J Jones, Tawin Iempridee, Xiaobin Wang, Hans C Lee, Janet E Mertz, Shannon C Kenney, Heather C Lin, Veerabhadran Baladandayuthapani, Christopher W Dawson, Jatin J Shah, Donna M Weber, Robert Z Orlowski
PURPOSE: Lenalidomide, thalidomide, and pomalidomide (LTP) are immunomodulatory agents approved for use in multiple myeloma, but in some settings, especially with alkylating agents, an increase in Hodgkin lymphoma and other secondary primary malignancies (SPM) has been noted. Some of these malignancies have been linked to Epstein-Barr virus (EBV), raising the possibility that immunomodulatory drugs disrupt latent EBV infection. EXPERIMENTAL DESIGN: We studied the ability of LTP to reactivate latently infected EBV-positive cell lines in vitro and in vivo, and evaluated the EBV viral load in archived serum samples from patients who received a lenalidomide, thalidomide, and dexamethasone (LTD) combination...
October 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Liping H Pettus, Kristin L Andrews, Shon K Booker, Jie Chen, Victor J Cee, Frank Chavez, Yuping Chen, Heather Eastwood, Nadia Guerrero, Bradley Herberich, Dean Hickman, Brian A Lanman, Jimmy Laszlo, Matthew R Lee, J Russell Lipford, Bethany Mattson, Christopher Mohr, Yen Nguyen, Mark H Norman, David Powers, Anthony B Reed, Karen Rex, Christine Sastri, Nuria Tamayo, Paul Wang, Jeffrey T Winston, Bin Wu, Tian Wu, Ryan P Wurz, Yang Xu, Yihong Zhou, Andrew S Tasker, Hui-Ling Wang
The high expression of proviral insertion site of Moloney murine leukemia virus kinases (Pim-1, -2, and -3) in cancers, particularly the hematopoietic malignancies, is believed to play a role in promoting cell survival and proliferation while suppressing apoptosis. The three isoforms of Pim protein appear largely redundant in their oncogenic functions. Thus, a pan-Pim kinase inhibitor is highly desirable. However, cell active pan-Pim inhibitors have proven difficult to develop because Pim-2 has a low Km for ATP and therefore requires a very potent inhibitor to effectively block the kinase activity at cellular ATP concentrations...
July 14, 2016: Journal of Medicinal Chemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"